激素难治性前列腺癌患者化疗的预后分析

Prognostic analysis of chemotherapy in patients with hormone refractory prostate cancer

目的探讨化疗治疗激素难治性前列腺癌（HRPC）患者的预后情况。方法20例HRPC患者给予化疗（10例予多西他赛联合泼尼松，10例予米托蒽联合泼尼松）3-17个周期，并根据化疗前血清PSA升高达到进入HRPC阶段首次测量PSA水平数值2倍所需的时间（PSADT）分为PSADT〈1．6个月（n=9）、≥1．6个月（n=11）两组，了解不同组别患者化疗有效率、疾病无进展生存时间（PFS）及总生存期情况。结果20例HRPC患者化疗有效率为55．0％，多西他赛组为70．0％，米托蒽组为40．0％；PSADT〈1．6个月组有效率为33．3％，≥1．6个月组为72．7％。PFS为1。16个月，平均（3．8±2．5）个月，多西他赛组为（4．8±1．1）个月，米托蒽组为（2．8±1．6）个月；PSADT〈1．6个月组为（2．7±0．4）个月，≥1．6个月组为（4．9±0．6）个月。总生存期为6-58个月，平均（28．6±6．3）个月，多西他赛组为（30．4±4．3）个月，米托蒽组为（27．3±5．4）个月；PSADT〈1．6个月组为（16．4±4．7）个月，≥1．6个月组为（31．2±5．6）个月。结论多西他赛化疗以及PSADT≥1．6个月的患者均可获得更高的化疗有效率和更长的PFS及生存期。但由于本研究样本量较小，仍需大样本研究进一步证实。

Objective To discuss the prognosis of chemotherapy in patients with hormone refractory prostate cancer （HRPC）. Methods 20 patients with HRPC were treated with 3-17 cycles of chemotherapy （10 cases with docetaxel plus prednisone, 10 cases with mitoxantrone plus prednisone）, and divided into PSADT 〈1.6 months group （n=9） and PSADT ≥1.6 months group （n=11）, then the chemotherapy efficiency, progression-free survival （PFS）, and overall survival （OS） were analyzed. Results The chemotherapy efficiency was 55.0% in 20 patients, 70.0% in docetaxel group, and 40.0% in mitoxantrone group; 33.3% in PSADT 〈1.6 months group, and 72.7% in PSADT ≥1.6 months group. PFS was 1-16 months, average （3.8±2.5） months in 20 patients, （4.8±1.1） months in docctaxel group, and （2.8±1 .6） months in mitoxantrone group; （2.7±0.4） months in PSADT 〈1.6 months group, and （4.9±0.6） months in PSADT ≥1.6 months group. OS was 6-58 months, average （28.6±6.3） months in 20 patients, （30.4±4.3） months in docetaxel group, and （27.3±5.4） months in mitoxantrone group; 06.4±4.7） months in PSADT 〈1.6 months group, and （31.2±5.6） months in PSADT ≥1.6 months group. Conclusions HRPC patients with PSADT ≥1.6 months and docetaxcl chemotherapy can obtain higher chemotherapy efficiency and longer PFS and survival. However, duc to the small sample size of the study, it is still necessary to bc further confirmed by large sample study.